BTIG Research boosted their price objective on shares of Climb Bio from $8.00 to $19.00 and gave the company a 'buy' rating in a report on Wednesday...
Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion and to provide updates on development plans and timelines for its lead...
JPMorgan Chase & Co. reduced its stake in Climb Bio, Inc. (NASDAQ:CLYM - Free Report) by 89.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and...
Shares of Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) have been assigned an average recommendation of "Buy" from the twelve analysts that are currently covering the stock, Marketbeat reports. One...